AMOXICILLIN AND CLAVULANATE POTASSIUM- amoxicillin and clavulanate potassium powder, for suspension United States - English - NLM (National Library of Medicine)

amoxicillin and clavulanate potassium- amoxicillin and clavulanate potassium powder, for suspension

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension usp and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension usp should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. amoxicillin and clavulanate potassium for oral suspension usp, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including beta-lactamase–producing strains), or m. catarrhalis (including beta-lactamase–producing strains) characterized by the following risk fa

Flucloxacillin 125mg/5ml Oral Solution BP Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 125mg/5ml oral solution bp

athlone laboratories ltd - flucloxacillin sodium - powder for oral solution - 125 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 125mg/5ml Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 125mg/5ml oral solution

athlone laboratories ltd - flucloxacillin sodium - powder for oral solution - 125 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 125mg/5ml Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 125mg/5ml oral solution

athlone pharmaceuticals limited - flucloxacillin sodium - powder for oral solution - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 125mg/5ml Oral Solution BP Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 125mg/5ml oral solution bp

athlone pharmaceuticals limited - flucloxacillin sodium - powder for oral solution - beta-lactamase resistant penicillins; flucloxacillin

Flucloxacillin 250mg/5ml Oral Solution Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 250mg/5ml oral solution

athlone laboratories ltd - flucloxacillin - oral solution - 250 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin

AMOXICILLIN- amoxicillin tablet, coated United States - English - NLM (National Library of Medicine)

amoxicillin- amoxicillin tablet, coated

lake erie medical dba quality care products llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. amoxicillin is indicated in the treatment of infections due to susceptible (only α -lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose and throat – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. infections of the genitourinary tract – due to e. coli, p. mirabilis, or e. faecalis. infections of the skin and skin structure – due to streptococcus spp. (α- and β -hemolytic strains only), staphylococcus spp. or e. coli. infections of the lower respiratory tract – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. gonorrhea, acute uncomplicated (ano-ge

AMOXICILLIN tablet, coated United States - English - NLM (National Library of Medicine)

amoxicillin tablet, coated

redpharm drug inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin 875 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. amoxicillin is indicated in the treatment of infections due to susceptible (only α -lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose and throat – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. infections of the genitourinary tract – due to e. coli, p. mirabilis, or e. faecalis. infections of the skin and skin structure – due to streptococcus spp. (α- and β -hemolytic strains only), staphylococcus spp. or e. coli. infections of the lower respiratory tract – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. gonorrhea, acute uncomplicated (ano-ge

AMOXICILLIN tablet, coated United States - English - NLM (National Library of Medicine)

amoxicillin tablet, coated

dispensing solutions, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. amoxicillin is indicated in the treatment of infections due to susceptible (only α -lactamase-negative) strains of the designated microorganisms in the conditions listed below: infections of the ear, nose and throat – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. infections of the genitourinary tract – due to e. coli, p. mirabilis, or e. faecalis. infections of the skin and skin structure – due to streptococcus spp. (α- and β -hemolytic strains only), staphylococcus spp. or e. coli. infections of the lower respiratory tract – due to streptococcus spp. (α- and β –hemolytic strains only), s. pneumoniae, staphylococcus spp., or h. influenzae. gonorrhea, acute uncomplicated (ano-ge

Flucloxacillin 125 mg/5 ml Powder for Oral Solution, Sugar Free Ireland - English - HPRA (Health Products Regulatory Authority)

flucloxacillin 125 mg/5 ml powder for oral solution, sugar free

brillpharma (ireland) limited - flucloxacillin sodium ph. eur. - powder for oral solution - 125 mg/5ml - beta-lactamase resistant penicillins; flucloxacillin